Trials / Completed
CompletedNCT01552005
Description of Drug Utilization and Assessment of Impact of Saxagliptin on Health Status of Patients With Type 2 Diabetes in France
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to respond to The French Health Authority which has requested BMS France and Astra Zeneca (AZ) France to set-up a long-term cohort study in a representative sample of French Type 2 Diabetes mellitus (T2D) patients treated with Saxagliptin to generate real world data on drug utilization, joint population, non comparative effectiveness and safety
Detailed description
Time Perspective: Ambispective cohort follow by a 18 to 24 month follow up period, Retrospective follow by Prospective.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Saxagliptin | No Intervention |
Timeline
- Start date
- 2012-05-01
- Primary completion
- 2015-06-01
- Completion
- 2015-06-01
- First posted
- 2012-03-13
- Last updated
- 2016-06-07
Source: ClinicalTrials.gov record NCT01552005. Inclusion in this directory is not an endorsement.